Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2015 1
2016 2
2017 2
2018 1
2019 1
2020 3
2021 11
2022 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Results by year

Filters applied: . Clear all
Page 1
A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs.
Réa D, Mauro MJ, Boquimpani C, Minami Y, Lomaia E, Voloshin S, Turkina A, Kim DW, Apperley JF, Abdo A, Fogliatto LM, Kim DDH, le Coutre P, Saussele S, Annunziata M, Hughes TP, Chaudhri N, Sasaki K, Chee L, García-Gutiérrez V, Cortes JE, Aimone P, Allepuz A, Quenet S, Bédoucha V, Hochhaus A. Réa D, et al. Among authors: aimone p. Blood. 2021 Nov 25;138(21):2031-2041. doi: 10.1182/blood.2020009984. Blood. 2021. PMID: 34407542 Free PMC article. Clinical Trial.
Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis.
Kantarjian HM, Hughes TP, Larson RA, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Boquimpani C, Pasquini R, Clark RE, Dubruille V, Flinn IW, Kyrcz-Krzemien S, Medras E, Zanichelli M, Bendit I, Cacciatore S, Titorenko K, Aimone P, Saglio G, Hochhaus A. Kantarjian HM, et al. Among authors: aimone p. Leukemia. 2021 Feb;35(2):440-453. doi: 10.1038/s41375-020-01111-2. Epub 2021 Jan 7. Leukemia. 2021. PMID: 33414482 Free PMC article. Clinical Trial.
PI3K inhibitors as new cancer therapeutics: implications for clinical trial design.
Massacesi C, Di Tomaso E, Urban P, Germa C, Quadt C, Trandafir L, Aimone P, Fretault N, Dharan B, Tavorath R, Hirawat S. Massacesi C, et al. Among authors: aimone p. Onco Targets Ther. 2016 Jan 7;9:203-10. doi: 10.2147/OTT.S89967. eCollection 2016. Onco Targets Ther. 2016. PMID: 26793003 Free PMC article. Review.
Pharmacokinetics of Asciminib When Taken With Imatinib or With Food.
Hoch M, Zack J, Quinlan M, Huth F, Forte S, Dodd S, Aimone P, Hourcade-Potelleret F. Hoch M, et al. Among authors: aimone p. Clin Pharmacol Drug Dev. 2022 Feb;11(2):207-219. doi: 10.1002/cpdd.1019. Epub 2021 Oct 5. Clin Pharmacol Drug Dev. 2022. PMID: 34609077
Smoothened inhibitor erismodegib combined with nilotinib in patients with chronic myeloid leukemia resistant/intolerant to at least one prior tyrosine kinase inhibitor: a phase 1b study.
Ottmann OG, Stegelmann F, Breccia M, Steegmann JL, Olavarria E, Aimone P, Lipton JH. Ottmann OG, et al. Among authors: aimone p. Leuk Lymphoma. 2021 Mar;62(3):739-742. doi: 10.1080/10428194.2020.1839649. Epub 2020 Nov 6. Leuk Lymphoma. 2021. PMID: 33153366 Clinical Trial. No abstract available.
Phase 2 study of nilotinib in pediatric patients with Philadelphia chromosome-positive chronic myeloid leukemia.
Hijiya N, Maschan A, Rizzari C, Shimada H, Dufour C, Goto H, Kang HJ, Guinipero T, Karakas Z, Bautista F, Ducassou S, Yoo KH, Zwaan CM, Millot F, Aimone P, Allepuz A, Quenet S, Hourcade-Potelleret F, Hertle S, Sosothikul D. Hijiya N, et al. Among authors: aimone p. Blood. 2019 Dec 5;134(23):2036-2045. doi: 10.1182/blood.2019000069. Blood. 2019. PMID: 31511239 Free PMC article. Clinical Trial.
A phase 2 study of nilotinib in pediatric patients with CML: long-term update on growth retardation and safety.
Hijiya N, Maschan A, Rizzari C, Shimada H, Dufour C, Goto H, Kang HJ, Guinipero T, Karakas Z, Bautista F, Ducassou S, Yoo KH, Zwaan CM, Millot F, Patterson B, Samis J, Aimone P, Allepuz A, Titorenko K, Sosothikul D. Hijiya N, et al. Among authors: aimone p. Blood Adv. 2021 Jul 27;5(14):2925-2934. doi: 10.1182/bloodadvances.2020003759. Blood Adv. 2021. PMID: 34309636 Free PMC article. Clinical Trial.
Correction to: Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis.
Kantarjian HM, Hughes TP, Larson RA, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Boquimpani C, Pasquini R, Clark RE, Dubruille V, Flinn IW, Kyrcz-Krzemien S, Medras E, Zanichelli M, Bendit I, Cacciatore S, Titorenko K, Aimone P, Saglio G, Hochhaus A. Kantarjian HM, et al. Among authors: aimone p. Leukemia. 2021 Jul;35(7):2142-2143. doi: 10.1038/s41375-021-01306-1. Leukemia. 2021. PMID: 34108614 Free PMC article. No abstract available.
21 results